Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Primary Myelofibrosis 2Myeloproliferative Disorders 2Thrombocythemia, Essential 1Polycythemia Vera 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1

Interventions

Specimen Handling 5Biopsy 5Whole-Body Irradiation 3Mycophenolic Acid 3Cyclosporine 3Cyclophosphamide 3Azacitidine 3venetoclax 2ruxolitinib 2fludarabine phosphate 2decitabine and cedazuridine drug combination 2Sirolimus 2Melphalan 2Injections 2Granulocyte Colony-Stimulating Factor 2Decitabine 2Busulfan 2veliparib 1tocilizumab 1tagraxofusp 1posaconazole 1peginterferon alfa-2b 1iadademstat 1gilteritinib 1fludarabine 1fedratinib 1axatilimab 1Tranexamic Acid 1Topotecan 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic-Myeloproliferative Diseases × fedratinib × 90 days × Clear all
NCT04282187 2026-03-16

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

University of Washington

Phase 2 Recruiting
25 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡